Accession Number:

ADA528212

Title:

The Effect of Human Immunodeficiency Virus on Hepatitis B Virus Serologic Status in Co-Infected Adults

Descriptive Note:

Journal article

Corporate Author:

UNIFORMED SERVICES UNIV OF THE HEALTH SCIENCES BETHESDA MD

Report Date:

2010-01-01

Pagination or Media Count:

9.0

Abstract:

Background Factors associated with serologic hepatitis B virus HBV outcomes in HIV-infected individuals remain incompletely understood, yet such knowledge may lead to improvements in the prevention and treatment of chronic HBV infection. Methods and Findings HBV-HIV co-infected cohort participants were retrospectively analyzed. HBV serologic outcomes were classified as chronic, resolved, and isolated-HBcAb. Chronic HBV CHBV was defined as the presence of HBsAg on two or more occasions at least six months apart. Risk factors for HBV serologic outcome were assessed using logistic regression. Of 2037 participants with HBV infection, 281 14 had CHBV. Overall the proportions of HBV infections classified as CHBV were 11, 16, and 19 for CD4 cell count strata of 500, 200499, and ,200, respectively p,0.0001. Risk of CHBV was increased for those with HBV infection occurring after HIV diagnosis OR 2.62 95 CI 1.783.85. This included the subset with CD4 count 500 cellsmL where 21 of those with HBV after HIV diagnosis had CHBV compared with 9 for all other cases of HBV infection in this stratum p 0.0004. Prior receipt of HAART was associated with improved HBV serologic outcome overall p 0.012, and specifically among those with HBV after HIV p 0.002. In those with HBV after HIV, HAART was associated with reduced risk of CHBV overall OR 0.18 95 CI 0.040.79 including reduced risk in the subsets with CD4 350 cellsmL p,0.001 and CD4 500 cellsmL p 0.01 where no cases of CHBV were seen in those with a recent history of HAART use. Conclusions Clinical indicators of immunologic status in HIV-infected individuals, such as CD4 cell count, are associated with HBV serologic outcome. These data suggest that immunologic preservation through the increased use of HAART to improve functional anti-HBV immunity, whether by improved access

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE